

David Macdonald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6104305/publications.pdf>

Version: 2024-02-01

13
papers

658
citations

1464605

7
h-index

1427216

11
g-index

13
all docs

13
docs citations

13
times ranked

789
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62.	0.8	62
2	Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e423-e427.	0.2	1
3	Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5793-5800.	3.2	20
4	Whole brain radiotherapy improves survival outcomes in primary CNS lymphoma patients ineligible for systemic therapy. <i>Supportive Care in Cancer</i> , 2020, 28, 5363-5369.	1.0	8
5	Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE™ Trial. <i>Blood</i> , 2020, 136, 38-39.	0.6	7
6	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE™ Study. <i>Blood</i> , 2020, 136, 24-26.	0.6	19
7	Does Upfront Autologous Stem Cell Transplant at First Relapse Improve Outcome in Transplant Eligible Follicular Lymphoma Patients Who Relapse within 24 Months. <i>Blood</i> , 2020, 136, 41-41.	0.6	0
8	Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8018-8018.	0.8	1
9	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410.	13.9	291
10	Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE™ Study. <i>Blood</i> , 2018, 132, 149-149.	0.6	20
11	Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8003-8003.	0.8	0
12	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 241-250.	5.1	212
13	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 59-74.	0.2	17